il-4(38-37)-pe38kdel
Recombinant proteinexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 1999 (NCT00003842)
Timeline
Indications
Mechanism of action
- Interleukin-4 receptor subunit alphaBINDING AGENT
IL4R binding agent
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- il-4(38-37)-pe38kdel
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00039052 | Phase 1 | Jan 1, 2002 | Neurocrine Biosciences |
| NCT00014677 | Phase 2 | Mar 1, 2001 | Neurocrine Biosciences |
| NCT00003842 | Phase 1 | Mar 1, 1999 | University of Cincinnati |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neurocrine Biosciences | For profit | 2 | 2 | 2 | 2001 |
| University of Cincinnati | Academic/Hospital | 1 | 1 | 1 | 1999 |
2 organizations
Page 1 / 1